000170142 001__ 170142 000170142 005__ 20260407115446.0 000170142 0247_ $$2doi$$a10.1016/j.isci.2026.115292 000170142 0248_ $$2sideral$$a148677 000170142 037__ $$aART-2026-148677 000170142 041__ $$aeng 000170142 100__ $$aSanz-García, Fernando$$uUniversidad de Zaragoza 000170142 245__ $$aAn assay toolkit for anti-tuberculosis drugs in the hollow fiber system 000170142 260__ $$c2026 000170142 5060_ $$aAccess copy available to the general public$$fUnrestricted 000170142 5203_ $$aThe hollow-fiber system for tuberculosis (HFS-TB) is an in vitro pharmacokinetic/pharmacodynamic (PKPD) tool qualified by the European Medicines Agency to support anti-TB drug development. It can simulate PK parameters of antimicrobials and feed in silico models to inform Phase II/III clinical trials. Yet, its implementation is challenging due to lack of consolidated technical guidelines, such as the compatibility of drugs with the most commonly used types of HFS-TB cartridges. Herein, we uncovered the compatibility of 10 anti-TB drugs alone: bedaquiline, clarithromycin, delamanid, ethambutol, isoniazid, linezolid, moxifloxacin, pretomanid, rifampicin and rifapentine; and a combination: bedaquiline-pretomanid-linezolid. The most hydrophilic compounds were within the compatibility range with all fibers; whereas the lipophilic ones required adjustments to be used in the system. Also, polysulfone and cellulose fibers were the most suitable for the tested drugs. Our data strengthen the importance of these preliminary studies and provide a useful toolkit towards wider HFS-TB implementation. 000170142 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000170142 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/submittedVersion 000170142 700__ $$aNdjogou, Dominique 000170142 700__ $$aAguilar-Ayala, Diana A.$$uUniversidad de Zaragoza 000170142 700__ $$aEveque-Mourroux, Maxime R. 000170142 700__ $$0(orcid)0009-0000-8481-7453$$aBenítez, Ana$$uUniversidad de Zaragoza 000170142 700__ $$aAznar, Sergio$$uUniversidad de Zaragoza 000170142 700__ $$aIsach-Traver, Nuria 000170142 700__ $$aMendoza-Losana, Alfonso 000170142 700__ $$aWilland, Nicolas 000170142 700__ $$0(orcid)0000-0002-0111-4697$$aLucía, Ainhoa$$uUniversidad de Zaragoza 000170142 700__ $$0(orcid)0000-0002-8480-0325$$aRamón-García, Santiago 000170142 700__ $$aERA4TB Consortium 000170142 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología 000170142 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000170142 7102_ $$10$$2X$$aUniversidad de Zaragoza$$bGrupos de investigación$$cG.I. Genética de Micob GENMICO 000170142 773__ $$g(2026), 115292 [51 pp.]$$piScience$$tISCIENCE$$x2589-0042 000170142 8564_ $$s3542070$$uhttps://zaguan.unizar.es/record/170142/files/texto_completo.pdf$$yPreprint 000170142 8564_ $$s959155$$uhttps://zaguan.unizar.es/record/170142/files/texto_completo.jpg?subformat=icon$$xicon$$yPreprint 000170142 909CO $$ooai:zaguan.unizar.es:170142$$particulos$$pdriver 000170142 951__ $$a2026-03-26-14:30:22 000170142 980__ $$aARTICLE